Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Are drug recalls always a good thing? - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Mar 6, 2013

    Are drug recalls always a good thing?

    As per the USFDA website - "A recall is when a product is removed from the market or a correction is made to the product because it is either defective or potentially harmful. Sometimes a company discovers a problem and recalls a product on its own. Other times a company recalls a product after FDA raises concerns".

    The USFDA conducts random checks on the batches of the drugs manufactured by the companies which are meant to be distributed in the US. During course of verification, if the USFDA finds any flaw, then it has the authority to direct the company to recall that batch of drug, where transgression has been detected.

    Both, companies on their own or the USFDA can initiate drug recall. Drug recalls are normally done in following circumstances: A drug contains some unwanted feature like any superfluous particle detected in it, the packing does not match as per norms, the drugs do not carry required warning, drug information is missing from the packets, and in various such circumstances and so on.

    When does a drug recall help companies?

    Whenever a drug is recalled, the manufacturer pulls back its defected inventory from the market. In some situations the manufacturer might have to recall its drugs on several occasions. In such situations, the manufacturer might temporarily stop the manufacturing if such defects are continuously perceived. In the course of these events, other generic producers get the opportunity to eat into the market share of the company facing drug defect problems. A company can take best advantage when it is manufacturing a drug which has low competition.

    Many companies have taken advantage of the situation when their competitors are facing manufacturing defects. They get more time to supply their drugs and grab market share. In light of these events we have taken Dr Reddy's as an example of a company which benefitted from its competitors having to recall their drugs.

    How did Dr Reddy's benefit?

    Dr Reddy's generates more than 50% of its revenues from the US business. It has a variety of products in the US which includes Para IVs and various low competition products. Tacrolimus and Lipitor too form part of the company's product basket. These drugs were recalled by other generic companies selling them and we shall take a look at whether Dr Reddy's was able to benefit from those events.

    Tacrolimus: There are few players selling the generic version of Prograf, generically known as Tacrolimus. Dr Reddy's was one among the early entrants to launch this product. The other peers were Mylan and Sandoz at its time of launch. Gradually, Dr Reddy's was able to gain 20% market share from this product. However since June 2012, Mylan had to recall its drugs due to some defects and is temporarily not selling it in the market. This has helped Dr Reddy's increase its market share from 20% to 40% as on date. Almost, doubling the revenues. However, Mylan might re-launch its generic version soon. As this product has low number of players, Dr Reddy's has generated better margin than other drugs. The branded market size of this drug was US$ 1 bn.

    Lipitor: Ranbaxy, Mylan, Sandoz Apotex, and Dr Reddy's are companies selling the generic versions of Lipitor in the US market. Recently, Ranbaxy had to recall its batches of drugs due to manufacturing defects. As Ranbaxy had 180-days exclusivity for this drug, it had gained 40% market share for it. Mylan too had grabbed sizeable market share. Dr Reddy's market share was in single digits before Ranbaxy recalled its drug. As per Dr Reddy's management, Mylan has taken large part of the share which was lost by Ranbaxy. Thus, although Dr Reddy's too has benefited from this recall, it has been very little. The branded market size of Lipitor was US$ 7 bn, before generics entered the market.

    Our view:

    Whether companies will benefit from drug recalls done by their competitors is a function of various factors such as the nature of the drug in question, the number of players selling it in the market and how long it takes to correct the manufacturing defects and launch it again. In many cases, companies have benefitted from drug recalls conducted by their competitors and gained market share. But it does not mean that that company will continue to witness better market share always. In the event that the company which was impacted by the drug recall, re-starts marketing its drug, there is the possibility that companies which had benefitted from the event may start losing market share.

    Whatever the case, investors need to have a cautious view on such events. The temporary increase in market share and thus in revenues might not last long.

      Bhavita Nagrani (Research Analyst) is a Chartered Financial Analyst (ICFAI) with nearly six years of experience in the field of equity research. She has a deep understanding of the global as well as the domestic Healthcare industry and keenly tracks the developments therein. When it comes to stock investing, she is a strong advocate of the bottom-up approach to stock picking and has a remarkable ability to discern nuances in the business models of companies belonging to the same industry. Bhavita is the contributor to our large cap franchise, StockSelect.



    Equitymaster requests your view! Post a comment on "Are drug recalls always a good thing?". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 17, 2017 (Close)